Effect of addition of G-CSF injection on level of hemoglobin in patients recieving hemodialysis who are unresponsive to erythropoietin injection.

Effect of Granulocyte colony stimulating factor on erythropoeitin hyporesponsive anemia in Chronic Kidney Disease patients on hemodialysis

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2019/04/018545

Enrollment

Registered

2019-04-10

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N186- End stage renal disease

Interventions

Intervention1: G-CSF injection: Patients resistant to EPO therapy will be recruited. Combination therapy of ESA plus G-CSF will be given as below. A)Epoetin alfa 20-50 units/kg s.c injection thrice

Eligibility

Inclusion criteria

Inclusion criteria: CKD-on Hemodialysis, receiving ESA at least 4 weeks with 1)baseline HB 2)no increase in Hb or increase Hb 3)age >18 years

Exclusion criteria

Exclusion criteria: 1) Pregnancy 2) Patient not willing to give consent for the study 3) Known allergy to G-CSF 4) Age 70 years 5) Thrombocytopenia 6) Sepsis

Design outcomes

Primary

Measure	Time frame
To study the effect of G-CSF on haemoglobin level in Erythropoeitin resistant or hyporesponsive anemia in CKD patients on hemodialysisTimepoint: at end of 1st, 2nd and 3rd month from starting therapy	—

Secondary

Measure	Time frame
To identify various factors associated with Erythropoeitin resistance Timepoint: At the beginning and at 3 months;To identify various factors associated with response and no response to the therapy Timepoint: at begining and 3rd month	—

Countries

India

Contacts

Public ContactC MALSAWMKIMKA

All India Institute of Medical Sciences Jodhpur

kimchhakchhuak@gmail.com9781874910

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026